Share:
MISSISSAUGA, Ontario and TORONTO, March 15, 2021 (GLOBE NEWSWIRE) Microbix Biosystems Inc. (TSX:MBX, OTCQB:MBXBF, Microbix®)), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene®), a provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce a collaboration under which Seegene will distribute and recommend Microbix s new COVID-variant Quality Assessment Products (QAPs™) to monitor the workflow accuracy of Seegene Allplex® assays across Canada.
In this collaboration, Seegene becomes a QAPs distributor and will recommend Microbix s whole-genome COVID-variant QAPs to support Seegene s molecular assays that detect the more-contagious emerging strains of the SARS-CoV-2 virus – initially the Brazilian, South African, & UK variants (P.1, B.1.351, & B1.1.7 respectively). Seegene s unique Allplex assays more rapidly and economically detect the genetic point-mutations associated
Microbix & Copan Italia Execute Strategic Agreement
MISSISSAUGA, Ontario and BRESCIA, Italy, Dec. 21, 2020 (GLOBE NEWSWIRE) Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix
®), a life sciences innovator and exporter, and Copan Italia S.p.A. (Copan
®), the global leader in specimen collection technologies, announce their execution of a strategic agreement (Agreement) in relation to Microbix’s quality assessment products (QAPs™) and Copan’s flocked devices (FLOQ
®).
The Agreement between Microbix and Copan expands upon an existing purchase and supply contract, adding licensing of Copan’s issued patents for use of flocked devices to format test controls (broadly known as QAPs). Also, it formalizes the parties’ agreement for joint usage of their respective brands for marketing of novel and innovative QAPs – Combining Copan’s well-known FLOQ
Microbix Reports Results for Fiscal 2020 marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Share:
MISSISSAUGA, Ontario, Dec. 15, 2020 (GLOBE NEWSWIRE) Microbix Biosystems Inc. (TSX:MBX, OTCQB:MBXBF, Microbix®)), a life sciences innovator and exporter, announces it has been invited to present about the performance of two types of its test-workflow Quality Assessment Products (QAPs™) at the 2020 virtual Scientific Meeting and Clinical Lab Expo of the American Association of Clinical Chemistry (AACC) taking place December 13-17, 2020.
The first abstract presentation is titled
Novel
Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control. It reviews performance of novel, innovative, & proprietary REDx™ (IVD) Mgen positive controls, and PROCEEDx™ (RUO) Mgen A2059G positive samples.